Fulcrum Therapeutics Inc (FULC) Stock Price, Quote & News

Company Profile

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Fa...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 651 8851

Website: www.fulcrumtx.com

Address:

26 Landsdowne Street, Cambridge, United States

StockConsultant Aug. 19 at 1:20 PM

$CMPX Compass Therapeutics stock, watch for an upside gap breakout, see also $FULC at https://www.stockconsultant.com/?CMPX Breakout trade WATCH for possible breakout above 2.47 Target: 2.96, 23.9% Stop: 2.21 Loss: 7.5% P/L ratio: 3.2 : 1 - Excellent BULLISH [Positioning] Intermediate trend bullish, Downtrend turned sideways, possible bottom. [Timing] Strong bullish 3 day candlestick pattern with Mild 3 day accumulation. [Timing] Average bullish 1 day moneyflow [Timing] breakout watch above 2.47, no resistance in area just above. BEARISH [Positioning] Short term typical rally, rally may start to slow. [Positioning] at resistance

0 · Reply

Zdxss1 Aug. 17 at 4:40 PM

$CMMB $FULC For Fulcrum (FULC): Fulcrum has only one clinical trial for migraine, which is currently in Phase 1. It previously had another clinical program that was discontinued. There are no other active clinical programs announced at present — only this single Phase 1 migraine study. For Chemomab (CMMB): Chemomab has a Phase 3 trial in PSC with exceptional regulatory alignment and excellent results. Additionally, there is a CVR of $40 million, which is conditional upon the first patient dose being administered.😡😡😡

0 · Reply

Zdxss1 Aug. 17 at 3:36 PM

$CMMB That is factually incorrect. $FULC did NOT pay a $250M pre-merger cash dividend to retail shareholders. The \bm{250M represents}FULC's total cash runway and liquidity balance on their balance sheet to fund ongoing operations through 2027 following their out-licensing deal with Sanofi. Clinical-stage biotechs do not issue cash dividends.

1 · Reply

MoneyFairyBlessings Aug. 17 at 2:21 PM

$FULC Breaking - out- looking.

0 · Reply

BiotechValues Aug. 17 at 1:53 PM

$HOWL - $FULC another reverse merger in record time (2.5 months since announcing S/A). Absolutely convinced $HOWL has an asset sale process in place given 6+ months and counting with no merger, and update a couple weeks ago suggests "updates" plural coming (aka asset sale + merger, etc)

0 · Reply

SDBiotechInvestor Aug. 17 at 1:40 PM

$CMMB - $FULC announcing $250 million pre merger cash dividend. Expect something similar before Scipher merger closes in regards to $40 P3 PSC CVR

2 · Reply

OpenOutcrier Aug. 17 at 12:18 PM

$FULC (+1.6% pre) Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies https://ooc.bz/l/111335

0 · Reply

notreload_ai Aug. 17 at 11:39 AM

$FULC and Slate merge to form Slate Medicines $SLTE, advancing SLTE-1009, a dual-target antibody for migraine prevention, with $245M in funding. https://notreload.xyz/xy/fulcrum-slate-merge-for-next-gen-migraine-therapies/

0 · Reply

The_Assassin Aug. 17 at 11:01 AM

$FULC solid news Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies

0 · Reply

focafoca99 Aug. 12 at 6:32 PM

$FULC notes a securities-law investigation by Kaplan Fox on behalf of investors.

0 · Reply

Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (FULC) for Potential Violations of the Federal Securities Laws

Aug 17, 2026, 8:43 AM EDT - 2 days ago

Fulcrum to merge with Slate in all-stock deal after drug setback

Aug 17, 2026, 8:00 AM EDT - 2 days ago

Fulcrum Therapeutics Transcript: M&A announcement

Aug 17, 2026, 8:00 AM EDT - 2 days ago

Fulcrum Therapeutics Press release: M&A announcement

2026-08-17T11:15:06.000Z - 2 days ago

Fulcrum Therapeutics, Slate Medicines to combine in an all-stock transaction

Aug 17, 2026, 7:00 AM EDT - 2 days ago

Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies

Jul 30, 2026, 7:00 AM EDT - 20 days ago

Fulcrum Therapeutics Quarterly report: Q2 2026

Jul 29, 2026, 10:30 AM EDT - 20 days ago

Kaplan Fox Notifies Fulcrum Therapeutics, Inc. (FULC) Investors of a Securities Investigation into the Company

Jul 17, 2026, 5:00 PM EDT - 4 weeks ago

Kaplan Fox Announces a Securities Investigation into Fulcrum Therapeutics, Inc. (FULC) - Investors Encouraged to Contact the Firm

2026-06-02T20:49:51.000Z - 2 months ago

Fulcrum Therapeutics downgraded to Underweight from Overweight at JPMorgan

2026-06-02T20:18:59.000Z - 2 months ago

Goldman suspends rating on Fulcrum Therapeutics

Jun 2, 2026, 12:56 PM EDT - 2 months ago

Fulcrum Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their Losses

2026-06-02T15:05:56.000Z - 2 months ago

Fulcrum Therapeutics price target lowered to $3 from $8 at BofA

Jun 2, 2026, 6:39 AM EDT - 2 months ago

Fulcrum plummets 50% after scrapping lead sickle-cell drug on FDA concerns

2026-06-02T10:34:23.000Z - 2 months ago

Fulcrum Therapeutics downgraded to Market Perform from Outperform at Leerink

2026-06-02T10:17:58.000Z - 2 months ago

Fulcrum Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

2026-06-02T10:06:35.000Z - 2 months ago

Fulcrum Therapeutics downgraded to Market Perform from Outperform at Leerink

2026-06-02T09:15:40.000Z - 2 months ago

Fulcrum Therapeutics downgraded to Hold from Buy at Truist

2026-06-02T08:45:09.000Z - 2 months ago

Piper double downgrades Fulcrum after sickle cell development stopped

2026-06-02T00:35:47.000Z - 2 months ago

Fulcrum Therapeutics downgraded to Underweight from Overweight at Piper Sandler

2026-06-02T00:30:10.000Z - 2 months ago

Fulcrum Therapeutics downgraded to Hold from Buy at Stifel

Jun 1, 2026, 5:10 PM EDT - 2 months ago

Fulcrum scraps sickle cell drug program after FDA raises cancer-risk concerns

2026-06-01T20:34:22.000Z - 2 months ago

Fulcrum discontinues pociredir program in SCD, initiates strategic review

Jun 1, 2026, 4:05 PM EDT - 2 months ago

Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review

2026-05-10T14:35:48.000Z - 3 months ago

Fulcrum Therapeutics price target raised to $8 from $7 at BofA

May 8, 2026, 4:30 PM EDT - 3 months ago

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Fulcrum Therapeutics Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Fulcrum Therapeutics Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Fulcrum Therapeutics Earnings Call Transcript: Q1 2026

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Fulcrum Therapeutics Earnings release: Q1 2026

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Fulcrum Therapeutics Quarterly report: Q1 2026

2026-04-27T11:56:41.000Z - 4 months ago

Fulcrum Therapeutics reports Q1 EPS (25c), consensus (30c)

Apr 27, 2026, 7:00 AM EDT - 4 months ago

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026

Apr 27, 2026, 6:55 AM EDT - 4 months ago

Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors

Apr 22, 2026, 7:00 AM EDT - 4 months ago

Fulcrum Therapeutics Slides: Corporate presentation

Apr 20, 2026, 8:00 AM EDT - 4 months ago

Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET

Mar 19, 2026, 8:00 AM EDT - 5 months ago

MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease

Mar 10, 2026, 1:00 PM EDT - 5 months ago

Fulcrum Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 6, 2026, 6:00 AM EST - 5 months ago

Fulcrum Therapeutics Slides: Corporate presentation

Mar 3, 2026, 8:30 AM EST - 6 months ago

Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference

Feb 24, 2026, 8:00 AM EST - 6 months ago

Fulcrum Therapeutics Earnings Call Transcript: Q4 2025

Feb 24, 2026, 8:00 AM EST - 6 months ago

Fulcrum Therapeutics Annual report: Q4 2025

Feb 24, 2026, 8:00 AM EST - 6 months ago

Fulcrum Therapeutics Earnings release: Q4 2025

Feb 24, 2026, 7:01 AM EST - 6 months ago

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025

Feb 24, 2026, 7:00 AM EST - 6 months ago

Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

Feb 17, 2026, 8:00 AM EST - 6 months ago

Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

Jan 14, 2026, 10:30 AM EST - 7 months ago

Fulcrum Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 10, 2026, 7:00 AM EST - 7 months ago

Fulcrum Therapeutics Slides: Corporate presentation

Jan 7, 2026, 8:00 AM EST - 8 months ago

Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 10, 2025, 7:48 AM EST - 9 months ago

Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants

Dec 8, 2025, 4:01 PM EST - 9 months ago

Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock

Dec 7, 2025, 7:00 AM EST - 9 months ago

Fulcrum Therapeutics Transcript: Status Update

Dec 7, 2025, 7:00 AM EST - 9 months ago

Fulcrum Therapeutics Press release: Status Update

Dec 7, 2025, 7:00 AM EST - 9 months ago

Fulcrum Therapeutics Slides: Status Update

Dec 6, 2025, 5:30 PM EST - 9 months ago

Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting

Dec 2, 2025, 8:30 AM EST - 9 months ago

Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025

Nov 3, 2025, 4:45 PM EST - 10 months ago

Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting

Oct 29, 2025, 8:00 AM EDT - 10 months ago

Fulcrum Therapeutics Earnings Call Transcript: Q3 2025

Oct 29, 2025, 8:00 AM EDT - 10 months ago

Fulcrum Therapeutics Quarterly report: Q3 2025

Oct 29, 2025, 8:00 AM EDT - 10 months ago

Fulcrum Therapeutics Earnings release: Q3 2025

Oct 29, 2025, 7:00 AM EDT - 10 months ago

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025

Oct 22, 2025, 8:54 AM EDT - 10 months ago

Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET

Sep 9, 2025, 2:00 PM EDT - 1 year ago

Fulcrum Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 1:35 PM EDT - 1 year ago

Fulcrum Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Aug 26, 2025, 8:00 AM EDT - 1 year ago

Fulcrum Therapeutics to Present at Upcoming Investor Meetings

Jul 29, 2025, 4:00 PM EDT - 1 year ago

Fulcrum Therapeutics Earnings release: Q2 2025

Jul 29, 2025, 4:00 PM EDT - 1 year ago

Fulcrum Therapeutics Quarterly report: Q2 2025

Jul 29, 2025, 6:48 AM EDT - 1 year ago

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025

Jul 29, 2025, 6:45 AM EDT - 1 year ago

Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

Jul 28, 2025, 4:01 PM EDT - 1 year ago

Fulcrum Therapeutics to Present Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

Jun 11, 2025, 8:00 AM EDT - 1 year ago

Fulcrum Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

May 29, 2025, 4:10 PM EDT - 1 year ago

Fulcrum Therapeutics to Present at Upcoming Medical Meetings

May 29, 2025, 8:30 AM EDT - 1 year ago

Fulcrum Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

May 21, 2025, 3:35 PM EDT - 1 year ago

Fulcrum Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 8, 2025, 4:05 PM EDT - 1 year ago

Fulcrum Therapeutics to Participate in Upcoming May Conferences

May 7, 2025, 8:00 AM EDT - 1 year ago

Fulcrum Therapeutics Proxy statement: Proxy Filing

May 1, 2025, 8:00 AM EDT - 1 year ago

Fulcrum Therapeutics Earnings Call Transcript: Q1 2025

May 1, 2025, 8:00 AM EDT - 1 year ago

Fulcrum Therapeutics Quarterly report: Q1 2025

May 1, 2025, 8:00 AM EDT - 1 year ago

Fulcrum Therapeutics Earnings release: Q1 2025

May 1, 2025, 7:00 AM EDT - 1 year ago

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Fulcrum Therapeutics Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Fulcrum Therapeutics Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Fulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 8:00 a.m. ET

StockConsultant Aug. 19 at 1:20 PM

0 · Reply

Zdxss1 Aug. 17 at 4:40 PM

0 · Reply

Zdxss1 Aug. 17 at 3:36 PM

1 · Reply

MoneyFairyBlessings Aug. 17 at 2:21 PM

$FULC Breaking - out- looking.

0 · Reply

BiotechValues Aug. 17 at 1:53 PM

0 · Reply

SDBiotechInvestor Aug. 17 at 1:40 PM

$CMMB - $FULC announcing $250 million pre merger cash dividend. Expect something similar before Scipher merger closes in regards to $40 P3 PSC CVR

2 · Reply

OpenOutcrier Aug. 17 at 12:18 PM

$FULC (+1.6% pre) Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies https://ooc.bz/l/111335

0 · Reply

notreload_ai Aug. 17 at 11:39 AM

0 · Reply

The_Assassin Aug. 17 at 11:01 AM

$FULC solid news Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies

0 · Reply

focafoca99 Aug. 12 at 6:32 PM

$FULC notes a securities-law investigation by Kaplan Fox on behalf of investors.

0 · Reply

focafoca99 Aug. 10 at 12:52 PM

$FULC elected Alan Musso as its new principal accounting officer, effective Aug. 7, after Greg Tourangeau's departure.

0 · Reply

focafoca99 Aug. 5 at 6:26 PM

$FULC receives a legal notice urging investors to contact Kaplan Fox about possible securities law violations.

0 · Reply

focafoca99 Jul. 31 at 2:58 PM

$FULC faces a securities-law investigation by Kaplan Fox, which is a legal notice rather than a company operating update.

0 · Reply

focafoca99 Jul. 29 at 5:02 PM

$FULC becomes the subject of a securities investigation by Kaplan Fox, a plaintiff law firm.

0 · Reply

NFA_DYOR Jul. 25 at 10:18 PM

$FULC Tang and me are keeping a close eye on this one. Any dip will be in my rader 👀

0 · Reply

focafoca99 Jul. 24 at 2:32 PM

$FULC alerts investors to a securities investigation by Kaplan Fox.

0 · Reply

StockConsultant Jul. 24 at 3:37 AM

$FULC Fulcrum Therapeutics stock, watch for an upside gap breakout at https://stockconsultant.com/?FULC Breakout trade WATCH for possible breakout above 3.93 Target: 4.75, 26.3% Stop: 3.55 Loss: 5.6% P/L ratio: 4.7 : 1 - Excellent BULLISH [Positioning] Intermediate trend bullish, Downtrend turned sideways, possible bottom. [Timing] Mild bullish 3 day candlestick pattern with Good 3 day accumulation. [Timing] Mild bullish 1 day moneyflow [Timing] breakout watch above 3.93, no resistance in area just above. BEARISH None

0 · Reply

FilingTracker Jul. 21 at 1:11 AM

$FULC More insider purchasing: https://filingtracker.ai/filing/1680581/0001178579-26-000016

0 · Reply

G101SPM Jul. 16 at 5:15 PM

#INSIDERS $FULC 10% owner Keven Tang (Tang Capital) bought another 249,946 shares at $3.54 - $3.55 worth approximately $891K (transaction dates 7/13-7/15). $HNRG Director bought 5,000 shares at $17.12 - $17.13 worth approximately $86K (transaction date 7/14). $SLGL 10% owner Opaleye Management bought 1,695 shares at $73.34 - $73.95 worth approximately $125K (transaction dates 7/13-7/14). $PB Director sold 1,100 shares worth approximately $80K (transaction date 7/15).

0 · Reply

GeneralGainz Jul. 16 at 3:25 PM

$SPRO CEO of Spero was CFO at $FULC this was the time frame she was there. Looking at their chart to see performance during her time there.

0 · Reply

FilingTracker Jul. 15 at 11:54 PM

$FULC Insider purchase: https://filingtracker.ai/filing/1178579/0001178579-26-000014?doc=form4-07152026_110717.xml

0 · Reply

Zackpedia Jul. 10 at 3:26 PM

$FULC You could’ve sold when I alerted and bought back at 3.4 now if you wanted.

0 · Reply

Market Cap	292.98M
Revenue (ttm)	0.00
Net Income (ttm)	-74.88M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	2,751,100
Avg Vol	2,419,900
Day's Range	N/A - N/A
Shares Out	76.30M
Stochastic %K	86%
Beta	3.05
Analysts	Hold
Price Target	$5.43